# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
ABBV-383 is a B-cell maturation antigen (BCMA) bispecific antibody T-cell engager being evaluated in relapsed/refractory multip...
HSBC analyst Rajesh Kumar upgrades AbbVie (NYSE:ABBV) from Hold to Buy and announces $185 price target.
Brenda Vingiello of Sand Hill Global Advisors named TJ Maxx's parent company, The TJX Companies Inc., as her final trade.
The positive opinion is based on results from two pivotal Phase 3 trials, INSPIRE and COMMAND, that evaluated the efficacy an...
New safety and efficacy data in heavily pre-treated patients with metastatic colorectal cancer (CRC), from a Phase 1 study of A...